How Methotrexate Affects Kidney Function

Methotrexate can damage the kidneys primarily by forming crystals inside the tiny tubes that filter and concentrate urine, a process called crystalline nephropathy. At high doses used in cancer treatment, acute kidney injury occurs in roughly 2% to 12% of patients. At the low doses prescribed for autoimmune conditions like rheumatoid arthritis, the picture is more nuanced and, in some respects, surprisingly different from what you might expect.

Why the Kidneys Bear the Burden

The kidneys are the main exit route for methotrexate. At high doses, about 90% of the drug leaves the body through the kidneys without being chemically changed first. The kidneys filter it, actively pump it into the tubular fluid, and partially reabsorb it. That heavy reliance on the kidneys means that anything slowing kidney function also slows methotrexate clearance, and lingering methotrexate can then do more damage to the kidneys, creating a vicious cycle.

This feedback loop is what makes methotrexate nephrotoxicity especially dangerous in high-dose settings. Impaired kidney function delays drug clearance, and prolonged exposure to toxic concentrations worsens kidney damage while simultaneously escalating non-kidney side effects like bone marrow suppression, mouth sores, and liver injury.

What Happens Inside the Kidney

Two intertwined mechanisms do the damage. The more visible one is crystallization. Methotrexate and its breakdown products are poorly soluble in acidic urine. When concentrations climb high enough, the drug precipitates into crystals inside the renal tubules, physically blocking them and injuring the tubular lining cells. Kidney biopsies from affected patients show distinctive crystal deposits in the tubule lumens. Under polarized light, these crystals exhibit birefringence, a property pathologists use to identify them definitively.

The second mechanism involves oxidative stress and mitochondrial dysfunction. Animal studies have shown that methotrexate ramps up the production of reactive oxygen species in kidney tissue, depletes the natural antioxidant glutathione, and disrupts mitochondrial function. The mitochondria lose membrane potential, their enzyme activity drops, and their energy output falls. Histological examination reveals a constellation of damage: inflammation between the tubules, tubular degeneration, shrunken glomeruli, and blood vessel congestion.

⁴

The reassuring piece is that this tubular damage is usually reversible. Once methotrexate levels drop, the tubular cells can regenerate, and kidney function tends to recover in most patients.

⁵

High-Dose Versus Low-Dose Methotrexate

The distinction between high-dose and low-dose methotrexate matters enormously for understanding kidney risk. High-dose methotrexate, generally defined as anything above 500 mg/m² of body surface area, is used to treat cancers like lymphoma and osteosarcoma. These infusions flood the kidneys with drug, making crystallization a real and well-documented threat.

Low-dose methotrexate, typically 25 mg per week or less, is a mainstay for rheumatoid arthritis, psoriasis, and other inflammatory conditions. Here the kidney story gets interesting. A large randomized trial (the CIRT trial, which enrolled thousands of patients with cardiovascular disease) found that low-dose methotrexate actually led to less decline in estimated kidney filtration rate compared to placebo. Patients on the drug had fewer kidney-related adverse events than those taking a sugar pill, with about three events per 100 person-years in the methotrexate group versus four per 100 person-years on placebo.

⁶

That finding caught researchers’ attention because inflammation itself is a driver of kidney function decline, and methotrexate’s anti-inflammatory properties may actually protect the kidneys at low doses. That said, not every study paints the same picture. An older study of rheumatoid arthritis patients on 15 mg of methotrexate weekly found a measurable drop in kidney filtration markers over the treatment period, suggesting that even low doses are not entirely without effect.

⁷

The difference in findings may come down to population, monitoring intensity, and how kidney function was measured. The bottom line for patients on low-dose methotrexate: the risk of serious kidney injury is far lower than with high-dose regimens, but periodic monitoring of kidney function remains standard practice.

Who Faces the Greatest Risk

Some patients are more vulnerable to methotrexate-related kidney problems than others, and clinicians factor in several risk elements before and during treatment.

Pre-existing kidney disease: Even mild-to-moderate reductions in kidney function slow methotrexate clearance, raising drug levels and the likelihood of toxicity. Methotrexate is contraindicated for rheumatoid arthritis patients whose estimated glomerular filtration rate falls below 30 mL/min. For those with moderate impairment (eGFR between 30 and 59), lower starting doses, slower dose escalation, and close monitoring are recommended.
Dehydration: Concentrated urine makes crystal formation far more likely. Patients who are not well-hydrated before and during methotrexate infusions face elevated risk.
Acidic urine: Methotrexate becomes much less soluble as urine pH drops. Urine that is acidic provides a perfect environment for crystal precipitation in the tubules.
Concurrent medications: Several drugs can interfere with methotrexate clearance. Non-steroidal anti-inflammatory drugs reduce kidney blood flow, and proton pump inhibitors can block the kidney transporters that pump methotrexate into the tubular fluid.
Genetic variation: Variants in genes involved in drug transport and metabolism, including genes in the solute carrier family (like SLC22A2) and cytochrome P450 genes (like CYP20A1), have been linked to differences in methotrexate toxicity.

⁸
⁹

Proton Pump Inhibitors and Other Drug Interactions

The interaction between methotrexate and proton pump inhibitors (PPIs) like omeprazole and pantoprazole deserves special attention because PPIs are among the most commonly prescribed drugs in the world. Laboratory research has shown that PPIs inhibit a kidney transporter called hOAT3, one of the proteins responsible for moving methotrexate from the blood into the tubular fluid for excretion. When hOAT3 is blocked, methotrexate hangs around in the bloodstream longer, reaching higher concentrations and increasing the risk of toxicity.

¹⁰

This interaction is clinically relevant for patients receiving high-dose methotrexate. If you are on a PPI and are about to start methotrexate, your oncology team will likely discuss pausing or switching the acid-reducing medication. For low-dose methotrexate, the stakes are lower because drug levels stay well below the threshold for crystal formation, but many rheumatologists still take note of concurrent PPI use.

How Clinicians Prevent Kidney Damage

Prevention is the cornerstone of safe high-dose methotrexate administration. Two measures are considered essential: aggressive hydration and urine alkalinization. The logic is straightforward. High fluid intake dilutes methotrexate in the tubular fluid, reducing the chance that concentrations reach the crystallization threshold. Making the urine alkaline (typically with intravenous sodium bicarbonate to keep urine pH above 7.0) increases the solubility of methotrexate, keeping it dissolved rather than forming crystals.

¹¹

European expert consensus guidelines emphasize that robust implementation of these supportive measures is critical. Alongside hydration and alkalinization, leucovorin (also called folinic acid) is given on a scheduled basis after methotrexate infusion. Leucovorin is not a kidney protector per se; it rescues normal cells from the toxic effects of methotrexate by providing them with the folate pathway products the drug blocks. This limits damage to the bone marrow, gut lining, and other rapidly dividing tissues even if methotrexate clearance is slower than expected.

¹²

Monitoring is tightly integrated with prevention. Serum creatinine and methotrexate blood levels are checked at defined time points after infusion, usually at 24 and 48 hours. Early research established that catching a rise in creatinine or a failure of methotrexate levels to fall on schedule allows clinicians to intensify rescue measures before severe toxicity takes hold.

¹³

More recent work suggests that calculating how fast methotrexate levels fall between time points (the elimination half-life) can predict kidney injury earlier still. One retrospective study found that a longer half-life between the second and third monitoring windows was independently associated with higher odds of acute kidney injury, even after accounting for age, dose, and baseline kidney function.

¹⁴

When Prevention Is Not Enough

Sometimes methotrexate levels stay dangerously high despite hydration, alkalinization, and leucovorin. This is called delayed methotrexate elimination, and it signals that the kidneys have already been injured enough to stall drug clearance. The immediate response is to intensify hydration and increase leucovorin doses, but there are situations where that is not sufficient.

Glucarpidase (sometimes referred to by its older name, carboxypeptidase G2) is an FDA-approved enzyme that breaks methotrexate down into inactive fragments directly in the bloodstream, bypassing the kidneys entirely. In patients with kidney injury after high-dose methotrexate, glucarpidase produces a rapid and sustained drop of 99% or more in serum methotrexate levels.

¹⁵

Expert consensus guidelines have tried to define precisely when glucarpidase should be used, because the drug is expensive and not always immediately available. The recommended approach is to identify patients whose methotrexate concentrations at specific time points after infusion exceed thresholds associated with severe or life-threatening toxicity, then administer glucarpidase promptly.

¹⁶

In hospitals where glucarpidase is unavailable or delayed, high-flux hemodialysis has emerged as a workable alternative. A case series reported that patients underwent an average of about five hemodialysis sessions, achieving a mean reduction of roughly 45% in serum methotrexate concentrations per session. The challenge is that methotrexate levels tend to rebound between sessions as the drug redistributes from tissues back into the blood, which is why multiple rounds are needed.

¹⁷

Some centers have explored combining hemodialysis with hemoadsorption using a specialized resin cartridge. Early case reports suggest this combination may remove methotrexate more effectively than hemodialysis alone, potentially serving as a bridge while waiting for glucarpidase.

¹⁸

Living With Reduced Kidney Function and Needing Methotrexate

A common clinical dilemma arises when someone with existing kidney impairment genuinely needs methotrexate, whether for cancer or for severe autoimmune disease that has not responded to other treatments. The drug is not automatically off the table for everyone with compromised kidneys, but the adjustments can be significant.

For rheumatoid arthritis and similar conditions, guidelines generally prohibit methotrexate when eGFR falls below 30 mL/min. Between 30 and 59 mL/min, clinicians may still prescribe it but at a lower starting dose, with slower increases and a lower maximum weekly dose. These patients require more frequent blood work to track both kidney function and methotrexate-related toxicity markers.

⁸

For high-dose cancer protocols in patients with borderline kidney function, the decision is more complex and typically involves multidisciplinary discussion between oncologists and nephrologists. Some protocols allow dose adjustments based on real-time creatinine clearance, while others substitute a different chemotherapy agent entirely. If the cancer in question responds uniquely well to methotrexate (as some central nervous system lymphomas do), the team may proceed cautiously with enhanced monitoring and have glucarpidase on standby.

Genetics and Individual Susceptibility

Not everyone receiving the same dose of methotrexate faces the same kidney risk, and genetics is part of the explanation. A study of rheumatoid arthritis patients treated with methotrexate identified several genetic variants associated with drug toxicity. The top markers were in genes involved in drug transport and metabolism: SLC22A2 (which encodes a kidney transporter), SLC7A7, CYP20A1, CYP39A1, and the mitochondrial enzyme gene ALDH2.

⁹

Pharmacogenomic testing is not yet standard practice before starting methotrexate, partly because the individual effect of any single variant is modest, and the clinical studies linking specific genotypes to actionable dose changes are still accumulating. But the field is moving in that direction. In pediatric oncology especially, where high-dose methotrexate is commonly used for bone cancers, there is growing interest in identifying children whose genetic profile puts them at higher risk for delayed drug clearance and kidney injury. Whether routine pre-treatment genotyping will eventually become standard depends on larger validation studies linking test results to measurable improvements in outcomes.

How Kidney Biopsies Tell the Story

Most patients who develop methotrexate-related kidney injury are diagnosed and managed based on blood tests (rising creatinine, slow decline in methotrexate levels) without ever needing a kidney biopsy. But when the clinical picture is unclear, or when kidney function fails to recover as expected, a biopsy can provide definitive evidence.

Under the microscope, methotrexate nephropathy has a characteristic appearance. The tubule lumens contain deposits that stain distinctively and show birefringence under polarized light, meaning the crystals bend light in a pattern unique to their molecular structure. On electron microscopy, the crystal material appears as amorphous, lobulated deposits that on higher magnification reveal short, wavy fibers or overlapping plaques. Importantly, standard tissue processing for electron microscopy does not destroy this birefringence, so pathologists can confirm the diagnosis using routine preparation techniques.

The biopsy findings also help distinguish methotrexate crystal nephropathy from other causes of acute kidney injury that might occur in cancer patients, such as tumor lysis syndrome, contrast dye injury, or drug reactions to other medications in a complex chemotherapy regimen. Getting the diagnosis right matters because the treatment is different: methotrexate nephropathy calls for drug-specific rescue with glucarpidase and aggressive hydration, not the interventions used for other forms of kidney injury.

1
ScienceDirect / Annals of Oncology. Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment
2
PubMed Central. Preventing and Managing Toxicities of High-Dose Methotrexate
3
PubMed Central. Kidney Biopsy Teaching Case: Methotrexate Crystals on Electron Microscopy of Kidney Biopsy for Acute Kidney Injury
4
Biomedicine & Pharmacotherapy. Mitochondrial dysfunction and oxidative stress are involved in the mechanism of methotrexate-induced renal injury and electrolytes imbalance
5
PubMed Central. Crystalline Nephropathy With High-Dose Methotrexate in a Patient With Primary CNS Lymphoma: A Case Report
6
PubMed Central. Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial
7
PubMed. Renal effects of low dose methotrexate in rheumatoid arthritis
8
PubMed Central. Overview of Methotrexate Toxicity: A Comprehensive Literature Review
9
PubMed Central. Genetic Variants Associated with Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results from the Treatment of Early Aggressive Rheumatoid Arthritis Trial
10
PubMed. Proton pump inhibitors inhibit methotrexate transport by renal basolateral organic anion transporter hOAT3
11
PubMed. Effect of urine pH and flow on renal clearance of methotrexate
12
PubMed Central. A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment
13
PubMed. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine
14
PubMed Central. Early therapeutic drug monitoring of methotrexate and its association with acute kidney injury: A retrospective cohort study
15
PubMed Central. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy
16
PubMed Central. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance
17
PubMed Central. High-flux hemodialysis as rescue therapy for high-dose methotrexate toxicity: case series and clinical insights
18
PubMed Central. Effective methotrexate removal by combined hemodialysis and polymeric resin hemoadsorption